The immunohistochemical expression of the inhibin/activin subunits is up-regulated by interferon-β1a in Ishikawa cell line

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 2005-2010

  Hoeing, Anna ^a   Kuhn, Christina ^a   Shabani, Naim ^a   Schulze, Sandra ^a   Gingelmaier, Andrea ^a   Dian, Darius ^a   Jeschke, Udo ^a   Friese, Klaus ^a   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Activin; Immunohistochemistry; Inhibin; Interferon; Ishikawa cells; Stimulation; Subunit

Indexed keywords

ACTIVIN; BETA1A INTERFERON; INHIBIN; INHIBIN ALPHA; INHIBIN BETA A; INHIBIN BETA B; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; UPREGULATION;

ACTIVINS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBINS; INTERFERON-BETA; UP-REGULATION;

EID: 34250708358     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W and Sawchenko P: Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44: 1-34, 1988.
2. de Kretser DM, Hedger MP, Loveland KL and Phillips DJ: Inhibins, activins and follistatin in reproduction. Hum Reprod Update 8: 529-541, 2002.
3. Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS and Friese K: Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol 122: 461-471, 2004.
4. Mylonas I, Jeschke U, Winkler L, Makovitzky J, Richter DU, Briese V and Friese K: Immunohistochemical expression of inhibin-alpha in human endometrium and the in vitro secretion of inhibin, estradiol and Cortisol in cultured human endometrial glandular cells. Arch Gynecol Obstet 268: 142-150, 2003.
5. Mylonas I, Winkler L, Jeschke U, Briese V and Friese K: Investigations on isolation, purification and cultivation of human endometrial cells and on the in vitro inhibin expression in glandular epithelial cells. Zentralbl Gynakol 125: 415-423, 2003.
6. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 93: 92-97, 2004.
7. Mylonas I, Makovitzky J, Fernow A, Richter DU, Jeschke U, Briese V, Gerber B and Friese K: Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. Arch Gynecol Obstet 272: 59-66, 2005.
8. Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U, Briese V and Friese K: Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem 108: 1-11, 2006.
9. Worbs S, Shabani S, Mayr D, Gingelmaier A, Makrigiannakis A, Kuhn C, Jeschke U, Kupka MS, Friese K and Mylonas I: Expression of inhibin/activin subunits (alpha, betaA and betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers. Oncol Rep 17(1): 97-104, 2007.
10. Risbridger GP, Ball EM, Wang H, Mellor SL and Peehl DM: Re-evaluation of inhibin alpha subunit as a tumor suppressor in prostate cancer. Mol Cell Endocrinol 225: 73-76, 2004.
11. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ and Bradley A: Alpha-inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 360: 313-319, 1992.
12. Verma S, Quirt I, McCready D, Bak K, Charette M and Iscoe N: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106: 1431-1442, 2006.
13. Middleton MR: Adjuvant interferon in the treatment of melanoma. Br J Cancer 80: 1679-1680, 1999.
14. Jahn B, Brieger J, Fenchel K, Mitrou PS and Bergmann L: In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1. Cancer Immunol Immunother 38: 304-310, 1994.
15. Brown TJ, Lioubin MN and Marquardt H: Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139: 2977-2983, 1987.
16. Hoshiya Y, Gupta V, Kawakubo H, Brachtel E, Carey JL, Sasur L, Scott A, Donahoe PK and Maheswaran S: Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. J Biol Chem 278: 51703-51712, 2003.
17. Cataldo NA, Fujimoto VY and Jaffe RB: Interferon-gamma and activin A promote insulin-like growth factor-binding protein-2 and -4 accumulation by human luteinizing granulosa cells, and interferon-gamma promotes their apoptosis. J Clin Endocrinol Metab 83: 179-186, 1998.
18. Petraglia F, Sacerdote P, Cossarizza A, Angioni S, Genazzani AD, Franceschi C, Muscettola M and Grasso G: Inhibin and activin modulate human monocyte chemotaxis and human lymphocyte interferon-gamma production. J Clin Endocrinol Metab 72: 496-502, 1991.
19. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F and Friese K: Expression of Inhibin/activin subunits alpha (-alpha), beta A (-beta (A)) and beta B (-beta (B)) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 37(1-2): 43-52, 2006.
20. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Schulze S, Kainer F and Friese K: Expression of Inhibin/Activin subunits alpha (-alpha), betaA (-betaA), and betaB (-betaB) in placental tissue of normal, preeclamptic, and HELLP pregnancies. Endocr Pathol 17: 19-34, 2006.
21. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K and Gerber B: Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis. Oncol Rep 13: 81-88, 2005.
22. Mylonas I, Speer R, Makovitzky J, Richter DU, Briese V, Jeschke U and Friese K: Immunohistochemical analysis of steroid receptors and glycodelin A (PP14) in isolated glandular epithelial cells of normal human endometrium. Histochem Cell Biol 114: 405-411, 2000.
23. Mylonas I, Jeschke U, Shabani N, Kuhn C, Balle A, Kriegel S, Kupka MS and Friese K: Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem 106: 245-252, 2004.
24. Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS and Friese K: Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 25: 1679-1686, 2005.
25. Mylonas I, Makovitzky J, Vogel M, Shabani N, Jeschke U and Friese K: Expression of inhibin/activin subunits, sialyl-Lewis A (CA 19-9, sLea) and sialyl-Lewis X (sLex) carbohydrate antigens in a hydatidiform mole with persistent polymorphic trophoblastic hyperplasia. Anticancer Res 25: 1725-1730, 2005.
26. Florio P, Severi FM, Cobellis L, Danero S, Bome A, Luisi S and Petraglia F: Serum activin A and inhibin A. New clinical markers for hydatidiform mole. Cancer 94: 2618-2622, 2002.
27. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di Blasio AM and Petraglia F: Serum and tissue expression of activin a in postmenopausal women with breast cancer. J Clin Endocrinol Metab 87: 2277-2282, 2002.
28. Matzuk MM and Bradley A: Identification and analysis of tumor suppressor genes using transgenic mouse models. Semin Cancer Biol 5: 37-45, 1994.
29. Cipriano SC, Chen L, Kumar TR and Matzuk MM: Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 141: 2319-2327, 2000.
30. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H and Bradley A: Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91: 8817-8821, 1994.
31. Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P and Petraglia F: Inhibin {alpha}-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur J Endocrinol 152: 277-284, 2005.
32. McCarthy SA and Bicknell R: Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268: 23066-23071, 1993.
33. Luisi S, Florio P, Reis FM and Petraglia F: Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 145: 225-236, 2001.
34. Chen YG, Lui HM, Lin SL, Lee JM and Ying SY: Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood) 227: 75-87, 2002.
35. Di Simone N, Crowley WF Jr, Wang QF, Sluss PM and Schneyer AL: Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137: 486-494, 1996.
36. Otani T, Minami S, Yamoto M and Umesaki N: Production of activin A in hyperplasia and adenocarcinoma of the human endometrium. Gynecol Oncol 83: 31-38, 2001.